Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal antibodies targeting CD38 (daratumumab) and s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Shih-Feng, Lin, Liang, Xing, Lijie, Yu, Tengteng, Wen, Kenneth, Anderson, Kenneth C., Tai, Yu-Tzu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698817/
https://www.ncbi.nlm.nih.gov/pubmed/31548533
http://dx.doi.org/10.3390/antib6040018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698817/
https://www.ncbi.nlm.nih.gov/pubmed/31548533
http://dx.doi.org/10.3390/antib6040018

Ejemplares similares